• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Inflammation and immunomodulatory therapies influence the relationship between ATP-binding cassette A1 membrane transporter-mediated cholesterol efflux capacity and coronary atherosclerosis in rheumatoid arthritis
CONCLUSION: ABCA1-CEC associated with decreased atherosclerosis in patients with below-median baseline and time-averaged CRP and bDMARD use. Conversely, ABCA1-CEC associated with increased plaque in those with higher CRP, corticosteroid users, methotrexate nonusers, and bDMARD nonusers. While in well-treated and controlled disease ABCA1-CEC appears atheroprotective, in uncontrolled RA its action may be masked or fail to counteract the inflammation-driven proatherogenic state.PMID:37520890 | PMC:PMC10371792 | DOI:10.1016/j.jtauto.2023.100209
Source: Atherosclerosis - July 31, 2023 Category: Cardiology Authors: George A Karpouzas Bianca Papotti Sarah R Ormseth Marcella Palumbo Elizabeth Hernandez Maria Pia Adorni Francesca Zimetti Matthew J Budoff Nicoletta Ronda Source Type: research

Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials
Introduction Inflammation is emerging as an important risk factor for atherosclerotic cardiovascular disease and has been a recent target for many novel therapeutic agents. However, comparative evidence regarding efficacy of these anti-inflammatory treatment options is currently lacking. Methods and analysis This systematic review will include randomised controlled trials evaluating the effect of anti-inflammatory agents on cardiovascular outcomes in patients with known cardiovascular disease. Studies will be retrieved from Medline, Embase, the Cochrane Central Register of Controlled Trials, as well as clinical trial regi...
Source: BMJ Open - June 27, 2022 Category: General Medicine Authors: Boczar, K. E., Shin, S., Bezzina, K. A., Geejo, A., Pearson, A. L., Shahab, S., Fehlmann, C. A., Visintini, S., Beanlands, R., Wells, G. A. Tags: Open access, Cardiovascular medicine Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: An updated meta-analysis
Conclusion: MTX can prevent CVEs in RA patients, but there is not sufficient evidence for using MTX to treat patients with CHD.
Source: Medicine - February 19, 2021 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis.
CONCLUSION: Abatacept and TNFi were associated with decreased risk of CVD compared to csDMARDs. Minimizing glucocorticoid use and optimizing MTX dose may improve CV outcomes in patients with RA. PMID: 32801134 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - August 18, 2020 Category: Rheumatology Tags: J Rheumatol Source Type: research

Cardiovascular comorbidities in rheumatoid arthritis.
Abstract Approximately 80% of patients with rheumatoid arthritis (RA) suffer from comorbidities including more than 50% from cardiovascular (CV) diseases. Inflammatory activity is the main factor connecting RA with atherosclerosis, coronary heart disease, stroke, thromboembolic events and heart failure. Altogether these affect RA patients twice as frequently as the general population and CV events are the major cause of death in RA. Besides inflammatory activity, which can be reduced or eliminated by optimal treatment and controlling the RA activity, traditional CV risk factors also contribute to the total CV ris...
Source: Zeitschrift fur Rheumatologie - January 17, 2019 Category: Rheumatology Authors: Krüger K, Nüßlein H Tags: Z Rheumatol Source Type: research

Rapidly Fatal Internal Carotid Artery Mycotic Aneurysm Rupture in a Rheumatoid Patient Taking a TNF-α Inhibitor: Case Report and Literature Review
Conclusions Although fungal mycotic aneurysms of the ICA are rare, their incidence may increase with the expanded use of immunosuppressive medications. Patients with rheumatoid arthritis who take potent immunosuppression regimens may be prime candidates for mycotic aneurysms because they often have two favoring conditions: atherosclerosis and immunosuppression. These ICA aneurysms carry a high mortality rate, so early diagnosis and aggressive therapy, potentially by endovascular trapping/vessel occlusion coupled with long-term antifungal therapy, is essential.[...]Georg Thieme Verlag KG Stuttgart · New YorkArticle in Th...
Source: Journal of Neurological Surgery Part A: Central European Neurosurgery - July 21, 2014 Category: Neurosurgery Authors: Bowers, Christian A.Saad, DanyClegg, Daniel O.Ng, PerryClayton, FredericHaydoura, SouhaSchmidt, Richard H. Tags: Case Report Source Type: research

Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis
Background: Inflammation plays a fundamental role in atherothrombosis. Yet, whether direct inhibition of inflammation will reduce the occurrence of adverse cardiovascular outcomes is not known.Design: The Cardiovascular Inflammation Reduction Trial (CIRT) (ClinicalTrials.gov NCT01594333) will randomly allocate 7,000 patients with prior myocardial infarction (MI) and either type 2 diabetes or the metabolic syndrome to low-dose methotrexate (target dose 15-20 mg/wk) or placebo over an average follow-up period of 3 to 5 years. Low-dose methotrexate is a commonly used anti-inflammatory regimen for the treatment of rheumatoid a...
Source: American Heart Journal - May 6, 2013 Category: Cardiology Authors: Brendan M. Everett, Aruna D. Pradhan, Daniel H. Solomon, Nina Paynter, Jean MacFadyen, Elaine Zaharris, Milan Gupta, Michael Clearfield, Peter Libby, Ahmed A.K. Hasan, Robert J. Glynn, Paul M. Ridker Tags: Trial Design Source Type: research